Dewpoint Therapeutics
Jesse Lai is a Senior Scientist at Dewpoint Therapeutics. Jesse has a background in human stem cells and has been researching neurodegenerative diseases for over 10 years. Jesse is currently leading a team that is assessing the MOA of new targets.
Jesse started their career as a Visiting Research Scientist at Sanquin, where they studied the effects of blood transfusions on patients with thalassemia. After 4 months, they moved to Queen's University, where they worked as an Enrichment Studies Unit Instructor and a Graduate Teaching Assistant - PATH310: Pathology and Molecular Medicine. Jesse also served as a 4th year undergraduate research mentor and a Conservation Genetics Research Assistant.
After 6 years at Queen's University, Jesse moved to the Keck School of Medicine of the University of Southern California as a Postdoctoral Fellow. During their 3 years at USC, they researched human stem cells and discovered novel therapeutic targets for neurodegenerative diseases. Jesse was also co-affiliated with Amgen Neuroscience and the Ichida Lab at USC.
In their current role as Senior Scientist at Dewpoint Therapeutics, Jesse is leading an iPSC disease modelling team and assessing the MOA of new targets.
Jesse Lai has a Bachelor of Science from Queen's University and a PhD in Immunology and Hematology from Queen's University.
Dewpoint Therapeutics
Dewpoint Therapeutics is the first company founded to apply the emerging discipline of biomolecular condensates to drug discovery. Dewpoint believes that a vast range of conditions has pathways that are regulated by condensates or arise from the dysfunction of condensates - including cancer, neurodegeneration, and metabolic disease.